pharmaphorum

Zuckerberg, Chan's Biohub launches protein 'world model'

Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...
pharmaphorum

FDA delays verdict on AZ breast cancer drug

After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...
pharmaphorum

Roche launches liver disease algorithm panel

Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...
pharmaphorum

Philanthropic drive puts $140m behind strep A vaccine

A $140 million fund has been launched by Coefficient Giving, a health-focused philanthropic organisation, to fund R&D into ...
pharmaphorum

Trustworthy and novel AI in clinical trial planning, with Kris Kaneta

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant ...
pharmaphorum

Newel Health, Gerresheimer team up to help pharma embrace digital

Digital medicine specialist Newel Health has formed an alliance with packaging group Gerresheimer to help pharma companies ...
pharmaphorum

Dynavax has GSK's shingles vaccine in its sights

Big pharma group GSK has been ruling the market for shingles vaccines for many years, but little Dynavax Technologies has aspirations to knock off its crown. The Emeryville, California-based biotech ...
pharmaphorum

Why Ireland has emerged as Europe’s biopharma hotspot

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...
pharmaphorum

Don’t sweat an FDA sIRB mandate in clinical research – It’s good news for everyone

We knew it was coming, and now it’s close. By the end of 2024, the US Food and Drug Administration (FDA) is expected to formally make reviews by a single institutional review board (sIRB) the standard ...
pharmaphorum

CRISPR biotech Intellia plummets as trial paused for safety

Gene-editing specialist Intellia Therapeutics lost more than 45% of its value in pre-market trading today as it revealed phase 3 trials of one of its two priority programmes had been suspended due to ...
pharmaphorum

Lilly gets back in infectious disease, via three M&A deals

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8 billion. At a stroke, the deals to acquire Curevo, LimmaTech ...
pharmaphorum

Sandoz gets first FDA OK for denosumab biosimilars

Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market. Amgen sells RANKL ...